Equitable Access to Gene Therapy: A Call to Action for the American Society of Gene and Cell Therapy.
作者信息
Cornetta Kenneth, Patel Kirtika, Wanjiku Christopher Mwaniki, Busakhala Naftali
机构信息
Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Department of Immunology, Moi University School of Medicine, Eldoret, Kenya.
出版信息
Mol Ther. 2018 Dec 5;26(12):2715-2716. doi: 10.1016/j.ymthe.2018.11.002. Epub 2018 Nov 16.
Abstract
摘要
相似文献
1
Equitable Access to Gene Therapy: A Call to Action for the American Society of Gene and Cell Therapy.公平获得基因治疗：对美国基因与细胞治疗学会的行动呼吁。
Mol Ther. 2018 Dec 5;26(12):2715-2716. doi: 10.1016/j.ymthe.2018.11.002. Epub 2018 Nov 16.
2
Applying the speed-dating model and other approaches to foster future leaders for the American Society of Gene and Cell Therapy.应用速配模式及其他方法为美国基因与细胞治疗学会培养未来的领导者。
Mol Ther. 2014 Aug;22(8):1397-1398. doi: 10.1038/mt.2014.119.
3
Pay-for-performance pricing for a breakthrough heart drug: learnings for cell and gene therapies.一种突破性心脏药物的绩效付费定价：细胞和基因疗法的经验教训
Regen Med. 2016 Apr;11(3):225-7. doi: 10.2217/rme-2016-0014. Epub 2016 Mar 16.
4
Improving the Affordability of Prescription Medications for People with Chronic Respiratory Disease. An Official American Thoracic Society Policy Statement.改善慢性呼吸道疾病患者的处方药可负担性。美国胸科学会官方政策声明。
Am J Respir Crit Care Med. 2018 Dec 1;198(11):1367-1374. doi: 10.1164/rccm.201810-1865ST.
5
6
American Physical Therapy Association environmental statement.
Phys Ther. 1992 May;72(5):378-94. doi: 10.1093/ptj/72.5.378.
7
Surgical Cost Disclosure May Reduce Operating Room Expenditures.手术费用披露可能会降低手术室支出。
Orthopedics. 2017 Mar 1;40(2):e269-e274. doi: 10.3928/01477447-20161116-03. Epub 2016 Nov 23.
8
European Society of Gene and Cell Therapy (ESGCT) at 25: A Gene Therapy Community at Its Prime and on the Move.
Hum Gene Ther. 2017 Nov;28(11):940. doi: 10.1089/hum.2017.29049.trf.
9
Let's not hide health costs.
Newsweek. 2007 Feb 5;149(6):52.
10
Full disclosure--out-of-pocket costs as side effects.完全披露——自付费用作为副作用。
N Engl J Med. 2013 Oct 17;369(16):1484-6. doi: 10.1056/NEJMp1306826.
引用本文的文献
1
Induced Pluripotent Stem Cells in Cardiomyopathy: Advancing Disease Modeling, Therapeutic Development, and Regenerative Therapy.诱导多能干细胞在心肌病中的应用：推动疾病建模、治疗开发和再生治疗
Int J Mol Sci. 2025 May 22;26(11):4984. doi: 10.3390/ijms26114984.
2
Breaking barriers: fostering equitable access to pediatric genomics through innovative care models and technologies.突破障碍：通过创新护理模式和技术促进儿科基因组学的公平获取。
Pediatr Res. 2025 Mar;97(4):1261-1268. doi: 10.1038/s41390-025-03859-8. Epub 2025 Jan 16.
3
Integrating Mitochondrial Biology into Innovative Cell Therapies for Neurodegenerative Diseases.将线粒体生物学融入神经退行性疾病的创新细胞疗法
Brain Sci. 2024 Sep 5;14(9):899. doi: 10.3390/brainsci14090899.
4
A multinational survey of potential participant perspectives on ocular gene therapy.一项关于潜在参与者对眼部基因治疗看法的跨国调查。
Gene Ther. 2024 May;31(5-6):314-323. doi: 10.1038/s41434-024-00450-4. Epub 2024 Apr 2.
5
Navigating Gene Therapy Access: The Case of Bulgaria in the Context of the EU Regulatory Landscape.探索基因疗法的可及性：以保加利亚在欧盟监管环境下的情况为例
Healthcare (Basel). 2024 Feb 11;12(4):458. doi: 10.3390/healthcare12040458.
6
The value-based price of transformative gene therapy for sickle cell disease: a modeling analysis.基于价值的镰状细胞病变革性基因治疗价格：建模分析。
Sci Rep. 2024 Feb 1;14(1):2739. doi: 10.1038/s41598-024-53121-0.
7
Implementation of a gene therapy education initiative by the ASGCT and Muhimbili University of Health and Allied Sciences.实施基因治疗教育计划由 ASGCT 和穆希比利大学卫生与联合科学学院。
Mol Ther. 2023 Sep 6;31(9):2561-2565. doi: 10.1016/j.ymthe.2023.07.019. Epub 2023 Aug 17.
8
Gene Therapy for Neuromuscular Diseases: Health Economic Challenges and Future Perspectives.基因治疗神经肌肉疾病：健康经济挑战与未来展望。
J Neuromuscul Dis. 2022;9(6):675-688. doi: 10.3233/JND-221540.
9
The Landscape of Early Clinical Gene Therapies outside of Oncology.非肿瘤领域早期临床基因治疗的现状。
Mol Ther. 2019 Oct 2;27(10):1706-1717. doi: 10.1016/j.ymthe.2019.09.002. Epub 2019 Sep 6.
本文引用的文献
1
Core outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project.血友病基因治疗的核心结局集：多利益相关者项目核心 HEM 的结果。
Haemophilia. 2018 Jul;24(4):e167-e172. doi: 10.1111/hae.13504. Epub 2018 May 20.
2
The financial burden and distress of patients with cancer: Understanding and stepping-up action on the financial toxicity of cancer treatment.癌症患者的经济负担和困境：了解并加强对癌症治疗的财务毒性的行动。
CA Cancer J Clin. 2018 Mar;68(2):153-165. doi: 10.3322/caac.21443. Epub 2018 Jan 16.
3
The state of gene therapy research in Africa, its significance and implications for the future.非洲基因治疗研究的现状、其意义及对未来的影响。
Gene Ther. 2017 Sep;24(9):581-589. doi: 10.1038/gt.2017.57. Epub 2017 Jul 10.
4
Broadening Participation in the Sciences within and from Africa: Purpose, Challenges, and Prospects.在非及非洲内部扩大参与科学活动：目的、挑战与前景。
CBE Life Sci Educ. 2017 Summer;16(2). doi: 10.1187/cbe.15-12-0265.
5
Gene therapies development: slow progress and promising prospect.基因疗法的发展：进展缓慢但前景广阔。
J Mark Access Health Policy. 2017 Jan 3;5(1):1265293. doi: 10.1080/20016689.2017.1265293. eCollection 2017.
6
Global Health Equity: Cancer Care Outcome Disparities in High-, Middle-, and Low-Income Countries.全球健康公平性：高、中、低收入国家的癌症治疗结果差异
J Clin Oncol. 2016 Jan 1;34(1):6-13. doi: 10.1200/JCO.2015.62.2860. Epub 2015 Nov 17.
7
Glybera's second act: the curtain rises on the high cost of therapy.Glybera的第二幕：高昂治疗费用的帷幕拉开了。
Mol Ther. 2015 Feb;23(2):217-8. doi: 10.1038/mt.2014.248.
8
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.全球癌症发病与死亡：GLOBOCAN 2012 数据源、方法与主要模式。
Int J Cancer. 2015 Mar 1;136(5):E359-86. doi: 10.1002/ijc.29210. Epub 2014 Oct 9.
9
Reporting and grading financial toxicity.报告及分级财务毒性。
J Clin Oncol. 2014 Oct 10;32(29):3337-8. doi: 10.1200/JCO.2014.57.8740. Epub 2014 Sep 8.
10
World Primary Immunodeficiency Week: a call for newborn screening.世界原发性免疫缺陷病周：呼吁开展新生儿筛查。
Eur J Immunol. 2014 Apr;44(4):925-6. doi: 10.1002/eji.201470035.
Zotero 插件